autologous anti-BCMA chimeric antigen receptor T cells
BCRITP
Phase 2 mab active
Quick answer
autologous anti-BCMA chimeric antigen receptor T cells for ITP is a Phase 2 program (mab) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- ITP
- Phase
- Phase 2
- Modality
- mab
- Status
- active